Cardiology overview cardiomyopathy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
==Hypertrophic Obstructive Cardiomyopathy== | ==Hypertrophic Obstructive Cardiomyopathy== | ||
===Screening=== | |||
* Athletes should be screened using a family history of sudden death and a murmur on physical examination. Electrocardiograms and echocardiograms are not cost effective in this population. | * Athletes should be screened using a family history of sudden death and a murmur on physical examination. Electrocardiograms and echocardiograms are not cost effective in this population. | ||
===Prognosis=== | |||
* The myosin binding proteins C genetic variant carries a good prognosis. | * The myosin binding proteins C genetic variant carries a good prognosis. | ||
===Treatment=== | |||
* Atrial fibrillation should be managed with amiodarone | |||
==References== | ==References== | ||
Revision as of 20:55, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Hypertrophic Obstructive Cardiomyopathy
Screening
- Athletes should be screened using a family history of sudden death and a murmur on physical examination. Electrocardiograms and echocardiograms are not cost effective in this population.
Prognosis
- The myosin binding proteins C genetic variant carries a good prognosis.
Treatment
- Atrial fibrillation should be managed with amiodarone